Premium
Preclinical evaluation of nanoparticle albumin‐bound paclitaxel for treatment of pediatric bone sarcoma
Author(s) -
Wagner Lars M.,
Yin Hong,
Eaves David,
Currier Mark,
Cripe Timothy P.
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25062
Subject(s) - gemcitabine , medicine , paclitaxel , docetaxel , sarcoma , oncology , chemotherapy , osteosarcoma , pancreatic cancer , cancer , cancer research , pathology
The combination of docetaxel and gemcitabine is frequently used to treat recurrent bone sarcoma. Nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) is less toxic and more active than docetaxel or paclitaxel for breast cancer patients. The combination of nab‐paclitaxel and gemcitabine has preclinical synergy and is approved to treat pancreatic cancer. We observed growth inhibition and improved survival with nab‐paclitaxel in a Ewing sarcoma xenograft, and activity was additive with gemcitabine in an osteosarcoma model. Primary Ewing sarcoma tumors expressed the transport protein SPARC, previously associated with nab‐paclitaxel activity. These findings provide rationale for further evaluation of nab‐paclitaxel with gemcitabine for bone sarcoma. Pediatr Blood Cancer 2014;61:2096–2098. © 2014 Wiley Periodicals, Inc.